Melanoma trial testing a new injection with anti–PD-1 therapy
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies OH2 injection given directly into a melanoma tumor, combined with HX008, to see if it can shrink tumors after standard treatments—including PD-1—did not work. It may help people with advanced melanoma, especially when there is a reachable tumor for injection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have melanoma that is stage III (not operable) or stage IV, confirmed by pathology (biopsy).
- Your melanoma has progressed or you could not tolerate standard treatment, including PD-1 therapy; or PD-1 treatment helped before but the cancer came back within 6 months.
- Your general health is good enough for treatment (ECOG 0 to 1) and you’re expected to live more than 3 months.
- You have had prior cancer treatment, but it must be stopped long enough ago (at least 4 weeks; certain chemo needs more time) and side effects must be mild (grade 1 or better).
- There must be at least one measurable tumor that a clinician can inject (at least 5 mm at the longest point, and injection volume fits 1 mL).
- Blood tests and organ/liver/immune safety levels must be within allowed ranges, and pregnancy is not allowed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests OH2 injection in people with stage III or IV melanoma that has come back or spread after at least two prior treatment types. If you qualify, you may receive OH2 injection to help shrink tumors or slow disease progression.
This trial tests two new drugs, HX009 and IN10018, with or without standard chemotherapy, for people with advanced solid tumors that haven't responded to treatment or have no standard options. It aims to see if this combination can help shrink or control the cancer.
This trial tests a new drug called PRJ1-3024 for people with advanced melanoma that has not responded to standard treatment. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This Phase 1/2 study tests a medicine injected directly into a tumor, alone or with pembrolizumab (an immune-therapy drug given through a vein). It is for people with advanced or metastatic solid cancers that have grown despite standard treatments, aiming to improve tumor control.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
This trial tests a new cell therapy made from your own tumor-fighting cells (TILs) for advanced melanoma that hasn't responded to other treatments. It aims to shrink tumors by re-infusing these boosted cells back into your body.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.